Ecklonia cava for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Ecklonia cava for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Concentrated extracts of an edible brown seaweed. The most consistently measured effect is a smaller blood-sugar rise after a starchy meal, with smaller, less certain reductions in cholesterol, body fat, blood pressure and night-time wakefulness. Most trials were run by sellers and judged low quality. Seaweed-derived products can carry enough iodine to unsettle the thyroid, and can concentrate arsenic. (Full Review)

Protocol

Standard supplement protocol
72–144 mg/day
Phlorotannin-standardised extract for at least 12 weeks
Glycemic protocol
600–1,500 mg/day
Dieckol-enriched extract immediately before the largest carbohydrate meal; exceeds the regulatory intake ceiling
Sleep protocol
500 mg
Standardised phlorotannin 30–60 minutes before bed
Time to effect
Post-meal glucose
Immediate
Blunting occurs within a single meal
Lipids, body fat, blood pressure
12 weeks
Changes took the full 12 weeks to become measurable, so shorter self-experiments show nothing
Sleep maintenance
1 week
Reduced wakefulness after falling asleep was measured in a one-week trial

Benefits

Contraindications
  • Pregnancy and lactation
  • Children under 12 years
  • Graves' disease, toxic nodular goitre, or Hashimoto thyroiditis with thyroid peroxidase antibodies above 60 IU/mL
  • Prior iodine-induced thyroid dysfunction, or urinary iodine above 300 µg/L
  • Known seaweed, algal or iodine hypersensitivity
  • Platelet count below 100 × 10⁹/L, or within 7 days of any surgery or dental extraction
  • Child-Pugh Class B or C liver impairment, or eGFR below 30 mL/min/1.73 m²
Key Interactions
  • Insulin and sulfonylureas (glimepiride, glipizide, gliclazide)
  • α-Glucosidase inhibitors (acarbose, miglitol) and gut-hormone-based drugs (sitagliptin, semaglutide)
  • Levothyroxine and antithyroid drugs (methimazole, propylthiouracil)
  • Sedatives and hypnotics (lorazepam, zolpidem, gabapentin, pregabalin)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, low-dose aspirin)
  • Over-the-counter medications (NSAIDs: ibuprofen, naproxen, aspirin; sedating antihistamines: diphenhydramine, doxylamine; iodine-containing expectorants, potassium iodide)
  • Supplement interactions (non-heme iron and zinc binding)
  • Additive supplements affecting glucose (berberine, chromium picolinate, white kidney bean extract, cinnamon extract)
  • Additive supplements affecting sedation, bleeding and iodine (melatonin, valerian, L-Theanine, fish oil, nattokinase, high-dose vitamin E, kelp, bladderwrack)
  • Other interventions (prolonged fasting, ketogenic diets, post-bariatric-surgery anatomy)

Risk & Side Effects

  • High: Iodine overload and thyroid dysfunction from whole-alga forms
  • Medium: Arsenic and heavy-metal exposure from algal material; sedation and additive central nervous system depression
  • Low: Gastrointestinal intolerance; blood sugar falling too low with glucose-lowering therapy; bleeding-time prolongation
  • Speculative: Interference with drug metabolism; uncertainty at doses above the regulatory ceiling

Monitoring

Marker Target Why
Post-meal glucose (90 min) 100–120 mg/dL The effect with the strongest human support
Fasting glucose 75–86 mg/dL Detects drift in overall glycemic control
HbA1c 4.9–5.3% Integrates three months of glucose exposure
Fasting insulin <5 µIU/mL Tracks insulin resistance, which trials measured only indirectly
LDL cholesterol <100 mg/dL The lipid endpoint the pooled analysis moved
Apolipoprotein B <80 mg/dL Counts artery-damaging particles more reliably than LDL cholesterol
High-sensitivity C-reactive protein <0.5 mg/L Tests the anti-inflammatory claim directly
TSH 0.5–2.0 mIU/L Earliest signal of iodine-driven thyroid disturbance
Free T4 and free T3 Free T4 1.0–1.5 ng/dL; free T3 3.0–4.0 pg/mL Confirms whether a TSH shift is real
Thyroid peroxidase antibodies <9 IU/mL Identifies autoimmune thyroid disease, the main iodine contraindication
Urinary iodine 100–199 µg/L Quantifies the actual iodine load from any seaweed-derived product
Urinary inorganic arsenic (species-resolved) <15 µg/L Separates real arsenic exposure from harmless seafood forms
ALT 10–26 U/L (men), 10–19 U/L (women) Screens for any liver signal from a novel botanical
Platelet count and INR Platelets 150–400 × 10⁹/L; INR at the prescriber's target Bounds the theoretical bleeding risk
Ferritin 50–150 ng/mL Polyphenols reduce non-heme iron absorption

Cadence: Baseline, then two weeks of post-meal readings; thyroid and metabolic markers at 8–12 weeks, then every 6–12 months; urinary iodine at 12 weeks then annually; coagulation within two weeks on anticoagulants.

Qualitative Assessment

  • Sleep continuity — number and length of night-time awakenings
  • Morning sedation or slowed reaction time
  • Post-meal energy and sleepiness
  • Bloating, flatulence and stool consistency in the first two weeks
  • Cough and sputum burden, if used for respiratory symptoms
  • Waist circumference, measured monthly
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.